The popularity of Viagra initially sparked a surge for pharma, however recent developments present a complicated scenario for shareholders. Lower-cost competitors are reducing earnings, and ongoing litigation add more https://violavwrq780132.smblogsites.com/41275203/the-blue-pill-and-big-pharma-a-volatile-investment